Drug Profile
Research programme: gene editing therapeutics - Excision BioTherapeutics
Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Temple University
- Developer Excision BioTherapeutics
- Class Antivirals; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HTLV-I infections; Human papillomavirus infections
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in HTLV-I-infections in USA
- 28 Apr 2020 No recent reports of development identified for research development in Human-papillomavirus-infections in USA (Parenteral)
- 28 Apr 2020 No recent reports of development identified for research development in Progressive multifocal leukoencephalopathy in USA (Parenteral)